News

Oncology Pharma Announces the Appointment Of New Chief Financial Officer

San Francisco, CA – (NewMediaWire) – January 28, 2021 – Oncology Pharma Inc. (OTC: ONPH) is
pleased to announce that it has retained the services of Mr. James Smith, CPA
as its new Chief Financial Officer.  

Mr. James Smith, CPA is a
seasoned executive officer with experience encompassing multiple public and
private companies across a variety of industries.  His prior experience
includes CEO and/or CFO in two fully reporting SEC registrants as well as
numerous OTC Pink Sheet companies in either the CFO, outside accountant or CEO
capacities. In addition, during his employment with two national accounting
firms and in his own CPA firm practice, Mr. Smith has worked with multiple
Family Offices and investors in assisting them with their operations, capital
placement, organizational strategy and structure, with an emphasis on tax and
estate planning.  

 

“I very much look
forward to assisting the Oncology Pharma team as we further advance the
development and commercialization of several outstanding biotechnology
opportunities. There looks to be a lot of potential for the suite of
technologies assembled by the team and it is exciting to be a part of the
effort to bring to fruition the application of those technologies to real world
solutions to medical problems,” said Mr. Smith in response to his appointment.

Oncology Pharma is
pleased to welcome Mr. Smith aboard as the Company is working towards expanding
its portfolio and financing.

ABOUT ONCOLOGY PHARMA,
INC.

ONCOLOGY PHARMA, INC.
(OTCPK: ONPH) (the “Company”) is currently engaging in research and
development of therapeutics for oncology and prides itself for having a
world-class Advisory Board that keeps the Company in the forefront of
developing technologies in cancer research, biotechnology, and healthcare.

FORWARD LOOKING STATEMENTS

Certain of the matters
discussed in this announcement contain forward-looking statements that involve
material risks to and uncertainties in the Company’s business that may cause
actual results to differ materially from those anticipated by the statements
made herein. Such risks and uncertainties include risks related to licensing
arrangements and joint ventures, including the need to negotiate the definitive
agreements for the relationships; possible failure to realize anticipated
benefits of business relationships; and, costs of providing funding to these
business relationships. Other risks and uncertainties relating to the Company
include, among other things, current negative operating cash flows and a need
for additional funding to finance our operating plan; the terms of any further
financing, which may be highly dilutive and may include onerous terms;
unexpected costs and operating deficits, and lower than expected sales and
revenues; uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market acceptance;
adverse economic conditions; adverse results of any legal proceedings; the
volatility of our operating results and financial condition; inability to
attract or retain qualified senior management personnel, including sales and
marketing personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our ability to
possibly license from others patents and patent applications necessary to
develop products; the Company’s ability to implement its long range business
plan for various applications of its technology; the Company’s ability to enter
into agreements with any necessary marketing and/or distribution partners and with
any strategic or joint venture partners; the impact of competition; the
obtaining and maintenance of any necessary regulatory clearances applicable to
applications of the Company’s technology; management of growth; and, other
risks and uncertainties. This is not a solicitation to buy or sell securities
and does not purport to be an analysis of the Company’s financial position.

CONTACTS:

For additional
information, please contact the Oncology Pharma at:

One Sansome Street,
Suite 3500

San Francisco, CA
94104

Phone: 415-869-1038

Fax:
415-946-8801 

Email:
info@oncology-pharma.com

Source link

Show More

Related Articles

Back to top button